Zenocutuzumab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Zenocutuzumab
- DrugBank Accession Number
- DB15559
- Background
Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer
- Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
- Zenocutuzumab
- External IDs
- MCLA-128
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Zenocutuzumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Zenocutuzumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Zenocutuzumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Zenocutuzumab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- AE72RB1W1X
- CAS number
- 1969309-56-5
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Metastatic Breast Cancer 1 2 Recruiting Treatment Metastatic Castration-Resistant Prostate Cancer (mCRPC) / NSCLC Harboring NRG1 Fusion 1 2 Recruiting Treatment NRG1 Fusion / NSCLC Harboring NRG1 Fusion / Pancreatic Cancer Harboring NRG1 Fusion / Solid Tumours Harboring NRG1 Fusion 1 Not Available Available Not Available Breast Cancer / Cholangiocarcinoma / Colorectal Cancer / Head And Neck Cancer / Non-Small Cell Lung Cancer (NSCLC) / NRG1 Fusion / Pancreatic Cancer / Prostate Cancer / Renal Cell Carcinoma (RCC) / Solid Tumor, Unspecified, Adult / Unknown Primary Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 17, 2019 15:15 / Updated at February 21, 2021 18:55